Effect of Adjunctive Intracoronary Streptokinase on Late Term Left Ventricular Infarct Size and Volumes in Patients With Acute Myocardial Infarction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-31

Study Completion Date

2008-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesized that complementary intracoronary streptokinase administration to primary percutaneous intervention in patients with acute myocardial infarction may provide limitation infarct size and improvement in left ventricular volumes and function in acute and late phases (6 months).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction

NCT00302419

Acute Myocardial Infarction

COMPLETED PHASE4

Impact of Ischemic Post-conditioning

NCT04068116

ST Elevation Myocardial Infarction Ventricular Remodeling Ventricular Dysfunction +1 more

UNKNOWN NA

Comparison of Radial and Ulnar Artery Intervention in Patients With ST Elevated Myocardial Infarction

NCT04183140

ST Elevated Myocardial Infarction

COMPLETED NA

Intravenous Streptokinase in Acute Myocardial Infarction

NCT00000507

Cardiovascular Diseases Coronary Disease Heart Diseases +2 more

COMPLETED PHASE3

Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction

NCT05014061

Myocardial Ischemia

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndromes Acute Myocardial Infarction Reperfusion Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given

Group Type EXPERIMENTAL

Streptokinase

Intervention Type DRUG

intracoronary infusion, 250.000 Units

primary percutaneous coronary intervention

Intervention Type PROCEDURE

balloon catheter, stent

2

Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed

Group Type ACTIVE_COMPARATOR

primary percutaneous coronary intervention

Intervention Type PROCEDURE

balloon catheter, stent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Streptokinase

intracoronary infusion, 250.000 Units

Intervention Type DRUG

primary percutaneous coronary intervention

balloon catheter, stent

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Streptase (Streptokinase)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Continuous chest pain that lasted \> 30 minutes within the preceding 12 hours
* ST-segment elevation of at least 1 mm in 2 contiguous leads on the ECG
* Infarct related artery (IRA) occlusion (TIMI grade 0) at the angiography

Exclusion Criteria

* Contraindications to streptokinase, tirofiban, aspirin, clopidogrel, or heparin
* Culprit lesion in saphenous vein graft
* TIMI grade II-III flow in IRA
* Additional epicardial stenosis in the IRA distal to stented segment (significant or insignificant)
* Presence of left bundle branch block
* History of prior MI

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.